Do analysts recommend GANX or XCUR?

Gain Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 418.29%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Gain Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GANX or XCUR more profitable?

Exicure's return on equity of -179.41% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Exicure N/A -179.41% -64.37%

Does the media refer more to GANX or XCUR?

In the previous week, Gain Therapeutics and Gain Therapeutics both had 4 articles in the media. Exicure's average media sentiment score of 0.96 beat Gain Therapeutics' score of 0.63 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer XCUR or CYPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XCUR or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Cypherpunk Technologies N/A -48.33% -42.21%

Do analysts recommend SXTC or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, SXTC or XCUR?

China SXT Pharmaceuticals has higher revenue and earnings than Exicure. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.74M 38.66 -$3.30M N/A N/A Exicure $500K 35.16 -$4.95M -$1.55 N/A

Is SXTC or XCUR more profitable?

China SXT Pharmaceuticals' return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets China SXT Pharmaceuticals N/A N/A N/A Exicure N/A -179.41% -64.37%

Does the media favor SXTC or XCUR?

In the previous week, Exicure had 2 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 4 mentions for Exicure and 2 mentions for China SXT Pharmaceuticals. Exicure's average media sentiment score of 0.96 beat China SXT Pharmaceuticals' score of 0.94 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend EXOZ or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, EXOZ or XCUR?

Exicure has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 935.22 -$9.16M -$1.14 N/A Exicure $500K 35.16 -$4.95M -$1.55 N/A

Is EXOZ or XCUR more profitable?

Exicure's return on equity of -179.41% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Exicure N/A -179.41% -64.37%

Does the media favor EXOZ or XCUR?

In the previous week, Exicure had 2 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Exicure and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.98 beat Exicure's score of 0.96 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XCUR or FLNA?

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 278.79%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XCUR or FLNA more profitable?

Cassava Sciences' return on equity of -53.90% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Cassava Sciences N/A -53.90% -34.20%

Does the media refer more to XCUR or FLNA?

In the previous week, Exicure had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Exicure and 3 mentions for Cassava Sciences. Exicure's average media sentiment score of 0.96 beat Cassava Sciences' score of 0.51 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Exicure (XCUR) Competitors

$2.76 -0.09 (-3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$2.93 +0.17 (+6.16%)

As of 06:05 PM Eastern

Compare

XCUR vs. GANX, CYPH, SXTC, EXOZ, and FLNA

Should you buy Exicure stock or one of its competitors? MarketBeat compares Exicure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exicure include Gain Therapeutics (GANX), Cypherpunk Technologies (CYPH), China SXT Pharmaceuticals (SXTC), eXoZymes (EXOZ), and Cassava Sciences (FLNA). These companies are all part of the "pharmaceutical products" industry.

How does Exicure compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

In the previous week, Gain Therapeutics and Gain Therapeutics both had 4 articles in the media. Exicure's average media sentiment score of 0.96 beat Gain Therapeutics' score of 0.63 indicating that Exicure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Exicure has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,398.92	-$20.16M	-$0.58	N/A
Exicure	$500K	35.16	-$4.95M	-$1.55	N/A

Gain Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 418.29%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Gain Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure's return on equity of -179.41% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Exicure	N/A	-179.41%	-64.37%

Gain Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, indicating that its share price is 253% more volatile than the broader market.

Summary

Exicure beats Gain Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Exicure compare to Cypherpunk Technologies?

Exicure (NASDAQ:XCUR) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Cypherpunk Technologies' return on equity of -48.33% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Exicure had 3 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 4 mentions for Exicure and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Exicure's score of 0.96 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Exicure	Positive
Cypherpunk Technologies	Very Positive

Cypherpunk Technologies has lower revenue, but higher earnings than Exicure. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	35.16	-$4.95M	-$1.55	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

42.8% of Exicure shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Exicure has a beta of 3.53, indicating that its share price is 253% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

Summary

Exicure and Cypherpunk Technologies tied by winning 5 of the 10 factors compared between the two stocks.

How does Exicure compare to China SXT Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China SXT Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Exicure has a beta of 3.53, meaning that its stock price is 253% more volatile than the broader market.

China SXT Pharmaceuticals' return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Exicure	N/A	-179.41%	-64.37%

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Exicure had 2 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 4 mentions for Exicure and 2 mentions for China SXT Pharmaceuticals. Exicure's average media sentiment score of 0.96 beat China SXT Pharmaceuticals' score of 0.94 indicating that Exicure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China SXT Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

China SXT Pharmaceuticals has higher revenue and earnings than Exicure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.74M	38.66	-$3.30M	N/A	N/A
Exicure	$500K	35.16	-$4.95M	-$1.55	N/A

Summary

China SXT Pharmaceuticals and Exicure tied by winning 5 of the 10 factors compared between the two stocks.

How does Exicure compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Exicure's return on equity of -179.41% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Exicure	N/A	-179.41%	-64.37%

42.8% of Exicure shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

eXoZymes has a beta of 2.65, suggesting that its share price is 165% more volatile than the broader market. Comparatively, Exicure has a beta of 3.53, suggesting that its share price is 253% more volatile than the broader market.

Exicure has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	935.22	-$9.16M	-$1.14	N/A
Exicure	$500K	35.16	-$4.95M	-$1.55	N/A

In the previous week, Exicure had 2 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Exicure and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.98 beat Exicure's score of 0.96 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Exicure beats eXoZymes on 7 of the 11 factors compared between the two stocks.

How does Exicure compare to Cassava Sciences?

Exicure (NASDAQ:XCUR) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 278.79%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

42.8% of Exicure shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Exicure has higher revenue and earnings than Cassava Sciences. Exicure is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	35.16	-$4.95M	-$1.55	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Cassava Sciences' return on equity of -53.90% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Cassava Sciences	N/A	-53.90%	-34.20%

In the previous week, Exicure had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Exicure and 3 mentions for Cassava Sciences. Exicure's average media sentiment score of 0.96 beat Cassava Sciences' score of 0.51 indicating that Exicure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Exicure has a beta of 3.53, meaning that its share price is 253% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.71, meaning that its share price is 171% less volatile than the broader market.

Summary

Exicure beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.

Get Exicure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XCUR vs. The Competition

Export

Metric	Exicure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.17M	$3.28B	$6.41B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	N/A	18.99	24.46	23.62
Price / Sales	35.16	290.48	500.50	105.26
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	4.45	8.00	10.43	6.70
Net Income	-$4.95M	$23.89M	$3.56B	$337.26M
7 Day Performance	-10.39%	-3.49%	-1.39%	-1.41%
1 Month Performance	-18.10%	1.03%	0.86%	1.15%
1 Year Performance	-72.09%	34.39%	19.42%	22.61%

Exicure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XCUR Exicure	1.2498 of 5 stars	$2.76 -3.2%	N/A	-70.6%	$18.17M	$500K	N/A	50	News Coverage Short Interest Decrease
GANX Gain Therapeutics	2.368 of 5 stars	$1.65 -0.3%	$8.50 +416.7%	-13.6%	$70.16M	$50K	N/A	20	News Coverage Analyst Downgrade
CYPH Cypherpunk Technologies	0.5005 of 5 stars	$0.66 -2.5%	N/A	+64.5%	$70.12M	N/A	N/A	40	Positive News
SXTC China SXT Pharmaceuticals	1.1269 of 5 stars	$1.79 +14.7%	N/A	-99.5%	$68.41M	$1.74M	N/A	90	News Coverage
EXOZ eXoZymes	0.6397 of 5 stars	$7.80 flat	N/A	-44.1%	$66.14M	$70K	N/A	29	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XCUR) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exicure (XCUR) Competitors

XCUR vs. GANX, CYPH, SXTC, EXOZ, and FLNA

How does Exicure compare to Gain Therapeutics?

Summary

How does Exicure compare to Cypherpunk Technologies?

Summary

How does Exicure compare to China SXT Pharmaceuticals?

Summary

How does Exicure compare to eXoZymes?

Summary

How does Exicure compare to Cassava Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exicure (XCUR) Competitors

XCUR vs. GANX, CYPH, SXTC, EXOZ, and FLNA

How does Exicure compare to Gain Therapeutics?

Does the media refer more to GANX or XCUR?

Do insiders & institutionals believe in GANX or XCUR?

Which has better valuation & earnings, GANX or XCUR?

Do analysts recommend GANX or XCUR?

Is GANX or XCUR more profitable?

Which has more volatility & risk, GANX or XCUR?

Summary

How does Exicure compare to Cypherpunk Technologies?

Is XCUR or CYPH more profitable?

Do analysts prefer XCUR or CYPH?

Does the media prefer XCUR or CYPH?

Which has preferable valuation & earnings, XCUR or CYPH?

Do institutionals and insiders believe in XCUR or CYPH?

Which has more risk & volatility, XCUR or CYPH?

Summary

How does Exicure compare to China SXT Pharmaceuticals?

Do analysts recommend SXTC or XCUR?

Which has more risk and volatility, SXTC or XCUR?

Is SXTC or XCUR more profitable?

Do institutionals and insiders have more ownership in SXTC or XCUR?

Does the media favor SXTC or XCUR?

Which has stronger earnings and valuation, SXTC or XCUR?

Summary

How does Exicure compare to eXoZymes?

Is EXOZ or XCUR more profitable?

Do insiders & institutionals have more ownership in EXOZ or XCUR?

Which has more risk and volatility, EXOZ or XCUR?

Which has preferable valuation & earnings, EXOZ or XCUR?

Does the media favor EXOZ or XCUR?

Do analysts recommend EXOZ or XCUR?

Summary

How does Exicure compare to Cassava Sciences?

Do analysts rate XCUR or FLNA?

Do institutionals & insiders have more ownership in XCUR or FLNA?

Which has higher earnings and valuation, XCUR or FLNA?

Is XCUR or FLNA more profitable?

Does the media refer more to XCUR or FLNA?

Which has more risk and volatility, XCUR or FLNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools